ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2732

Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis

Maarten de Wit1, Alexis Ogdie2, Willemina Campbell3, Philip J Mease4, Niti Goel5, Laure Gossec6, Ying Ying Leung7, Christine Lindsay8, Penelope Palominos Jr.9, Ingrid Steinkoenig10, Suzanne Grieb11 and Ana-Maria Orbai12, 1Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, 2University of Pennsylvania, Philadelphia, PA, 3Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology Research, Swedish Medical Center, Seattle, WA, 5Quintiles; Duke University School of Medicine, Durham, NC, 6Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 7North District Hospital, Hong Kong, China, 8Medical Affairs, Amgen Inc, Thousand Oaks, CA, 9Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, 10Patient Research Partner, Cleveland, OH, 11Psychology, Johns Hopkins University, Baltimore, MD, 12Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Outcome measures, patient engagement and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Group for Research of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group recently obtained endorsement at the OMERACT 2016 conference for the updated PsA core domain set to be measured in PsA clinical trials.  Our objective was to integrate patients in each research phase such that the updated PsA core domain set fully reflects a diverse patient perspective.

Methods: The patient voice was sought through an international focus group study covering five continents, two surveys of patients, a consensus meeting with patients and physicians, as well as active partnership of five patient research partners (PRPs) from GRAPPA in the working group. Patient involvement was regularly discussed during reflection meetings by the research team.

Results: Overall, almost 150 persons with PsA were involved in the study: 1) Systematic literature review. Three PRPs were involved in study protocol development, analysis of results and co-authorship; 2) International focus group study. Ninety patients with PsA participated in 16 focus groups. PRPs gave feedback on the focus group guide, co-moderated focus groups and analyzed and interpreted qualitative data; 3) Surveys. Fifty patients participated in two rounds. Five PRPs participated in the design and analysis of the patient surveys and assisted in writing the introduction text; 4) Consensus meeting. Twelve patients participated in a face-to-face meeting with 12 physicians to agree on a preliminary core domain set. Two PRPs helped in preparing the agenda and patient participant selection.

In total 14 PRPs contributed to one or more of the above research activities. Challenges were identified by physician-researchers (time-constraints and tight deadlines; use of jargon; motivation of PRPs) as well as PRPs (ensuring equal participation and acknowledgement; involvement of pharmaceutical industry).

Conclusion: Collaboration between physician-researchers and PRPs during all core-set development steps enhanced the integration of the patient perspective in a meaningful and representative manner and provided additional face validity. PRP involvement in qualitative data analysis and development of the domain list for the surveys ensured that domains important to patients were maintained throughout the research process and phrased in a manner understandable to patients.

Figure 1. Flow chart of research activities with active participation of patients and patient research partners (PRP) in the update of the OMERACT Psoriatic Arthritis core domain set.

 

 


Disclosure: M. de Wit, None; A. Ogdie, None; W. Campbell, None; P. J. Mease, None; N. Goel, Quintiles, Inc., 3; L. Gossec, None; Y. Y. Leung, None; C. Lindsay, Amgen, Inc., 3,Amgen, Inc., 1; P. Palominos Jr., None; I. Steinkoenig, None; S. Grieb, None; A. M. Orbai, Celgene, 2,Janssen Pharmaceutica Product, L.P., 2,Janssen Pharmaceutica Product, L.P., 5.

To cite this abstract in AMA style:

de Wit M, Ogdie A, Campbell W, Mease PJ, Goel N, Gossec L, Leung YY, Lindsay C, Palominos P Jr., Steinkoenig I, Grieb S, Orbai AM. Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/meaningful-involvement-of-patients-in-the-development-of-a-core-outcome-set-for-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/meaningful-involvement-of-patients-in-the-development-of-a-core-outcome-set-for-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology